Rasem Mourad

Array ( [id] => 11108977 [patent_doc_number] => 20160305947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'IMMUNOHISTOCHEMICAL PROXIMITY ASSAY FOR PD-1 POSITIVE CELLS AND PD-LIGAND POSITIVE CELLS IN TUMOR TISSUE' [patent_app_type] => utility [patent_app_number] => 15/103050 [patent_app_country] => US [patent_app_date] => 2014-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22814 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15103050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107998 [patent_doc_number] => 20160304968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'Identification of Predictive Biomarkers Associated With WNT Pathway Inhibitors' [patent_app_type] => utility [patent_app_number] => 15/101242 [patent_app_country] => US [patent_app_date] => 2014-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 43736 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 49 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15101242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11094053 [patent_doc_number] => 20160291022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'Olfactomedin-4, Neudesin and Desmoplakin as Biomarkers of Breast Cancer' [patent_app_type] => utility [patent_app_number] => 15/038135 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 17726 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15038135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675283 [patent_doc_number] => 20160376375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => CSGP4 - Specific Chimeric Antigen Receptor for Cancer [patent_app_type] => utility [patent_app_number] => 15/038997 [patent_app_country] => US [patent_app_date] => 2014-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15038997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9932112 [patent_doc_number] => 20150080305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'APPLICATION OF INITIAL DOSES OF LHRH ANALOGUES AND MAINTENANCE DOSES OF LHRH ANTAGONISTS FOR THE TREATMENT OF HORMONE-DEPENDENT CANCERS AND CORRESPONDING PHARMACEUTICAL KITS' [patent_app_type] => utility [patent_app_number] => 14/550588 [patent_app_country] => US [patent_app_date] => 2014-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4808 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14550588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11463885 [patent_doc_number] => 09580504 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-02-28 [patent_title] => 'Pidilizumab monoclonal antibody therapy following stem cell transplantation' [patent_app_type] => utility [patent_app_number] => 14/536343 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16334 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14536343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10317288 [patent_doc_number] => 20150202291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER' [patent_app_type] => utility [patent_app_number] => 14/534158 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 19601 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14534158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10254946 [patent_doc_number] => 20150139943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY' [patent_app_type] => utility [patent_app_number] => 14/516880 [patent_app_country] => US [patent_app_date] => 2014-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 29733 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14516880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10362198 [patent_doc_number] => 20150247203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'COMPOSITION FOR DETECTING THE RESPONSE OF RECTAL ADENOCARCINOMAS TO RADIOCHEMOTHERAPY' [patent_app_type] => utility [patent_app_number] => 14/507707 [patent_app_country] => US [patent_app_date] => 2014-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20732 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14507707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9909039 [patent_doc_number] => 20150064240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'MUC1 Based Glycolipopeptide Vaccine with Adjuvant' [patent_app_type] => utility [patent_app_number] => 14/488767 [patent_app_country] => US [patent_app_date] => 2014-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25748 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14488767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10334654 [patent_doc_number] => 20150219659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'ASSAY' [patent_app_type] => utility [patent_app_number] => 14/489207 [patent_app_country] => US [patent_app_date] => 2014-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 7433 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14489207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11798536 [patent_doc_number] => 09539254 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-10 [patent_title] => 'Mutant ROS expression in human cancer' [patent_app_type] => utility [patent_app_number] => 14/483681 [patent_app_country] => US [patent_app_date] => 2014-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 40342 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14483681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12087704 [patent_doc_number] => 09841430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-12 [patent_title] => 'Fractional C-reactive protein (fracCRP) antibodies and assays' [patent_app_type] => utility [patent_app_number] => 14/482903 [patent_app_country] => US [patent_app_date] => 2014-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 21196 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14482903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011296 [patent_doc_number] => 20160208249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'Compositions and Methods for Inducing Senescence in Cancer Cells' [patent_app_type] => utility [patent_app_number] => 14/914928 [patent_app_country] => US [patent_app_date] => 2014-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 21376 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14914928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9895470 [patent_doc_number] => 20150050669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'METHOD AND KIT FOR ISOLATING TARGET CELL' [patent_app_type] => utility [patent_app_number] => 14/465336 [patent_app_country] => US [patent_app_date] => 2014-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8688 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14465336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10954662 [patent_doc_number] => 20140357684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'NOL3 IS A PREDICTOR OF PATIENT OUTCOME' [patent_app_type] => utility [patent_app_number] => 14/464394 [patent_app_country] => US [patent_app_date] => 2014-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 18313 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14464394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10954822 [patent_doc_number] => 20140357844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/460871 [patent_app_country] => US [patent_app_date] => 2014-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 40948 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14460871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799185 [patent_doc_number] => 20160145343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'ANTI-MUCIN 1 BINDING AGENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/904575 [patent_app_country] => US [patent_app_date] => 2014-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 35794 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14904575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11324977 [patent_doc_number] => 20160355588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'Bispecific CD3 and CD19 Antigen Binding Constructs' [patent_app_type] => utility [patent_app_number] => 14/903184 [patent_app_country] => US [patent_app_date] => 2014-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 35928 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14903184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10975629 [patent_doc_number] => 20140378664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'PROTEIN COMPLEX, BISPECIFIC ANTIBODY INCLUDING THE PROTEIN COMPLEX, AND METHOD OF PREPARATION THEREOF' [patent_app_type] => utility [patent_app_number] => 14/315068 [patent_app_country] => US [patent_app_date] => 2014-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 20927 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14315068 [rel_patent_id] =>[rel_patent_doc_number] =>)